CompletedNot Applicable

Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy

Italy102 participantsStarted 2022-02-21

Plain-language summary

This study aims to investigate the role of extracellular vesicles as diagnosic and prognostic biomarkers in patients with lymphomas or lymphoproliferative disorders. In particular, circulating extracellular vesicles, thanks to their cargo of proteins, lipids, and nucleic acids, play a role in the communication between cells. Since it has been described that these vesicles are able to influence also immune cells, the study of their functions may lead to the discovery of new mechanisms underlying this type of diseases.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria for patients: * Age ≥ 18 years. * Patients with WHO 2017-defined diagnosis of indolent and aggressive Non-Hodgkin Lymphoma (specifically Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Peripheral T-Cell Lymphoma, Mycosis Fungoides) or Chronic Lymphocytic Leukemia or Hairy Cell Leukemia or Multiple Myeloma. * Signed informed consent. Exclusion criteria for patients: \- Concomitant secondary neoplasia. Inclusion criteria for healthy donors: * Age ≥ 18 years. * Signed informed consent. Exclusion criteria for healthy donors: \- Healthy donors with neoplasia.

What they're measuring

Extracellular vesicle characterization

Timeframe: 2 years

Validation of extracellular vesicles as biomarker

Timeframe: 2 years

Trial details

NCT IDNCT06782854

SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-02-20

View on ClinicalTrials.gov More Diffuse Large B-Cell Lymphoma trials